The court was asked whether it was ‘desirable’ within the meaning of CPR rule 19.2(3) for Amgen, Inc. to cease to be a party to three claims relating to a European Patent (UK) entitled ‘G-CSF analog compositions and methods’ brought by Teva UK Ltd (in the case of the first and third claims) and by Teva Pharma BV and Teva UK Ltd (in the case of the second claim).
Arnold J
[2013] EWHC 3711 (Pat)
Bailii
England and Wales
Updated: 06 September 2021; Ref: scu.518486